Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Down 14.6% in March

Key Points

• Short interest down 14.6% in March to 5,491,622 shares (about 10.1% of shares sold short) with a days‑to‑cover ratio of 0.5, signaling reduced short positioning.
• Multiple law firms have issued investor alerts and class‑action notices regarding Aldeyra, with a May 29, 2026 lead‑plaintiff deadline, heightening potential litigation and settlement risk.
• Director Richard Douglas bought 70,000 shares at $1.40 on March 19 (a 56% increase in his stake); insiders now own 9.6% of the company while institutional investors hold roughly 59.7%.

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) was the recipient of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totaling 5,491,622 shares, a decrease of 14.6% from the March 15th total of 6,433,712 shares. Based on an average trading volume of 10,152,747 shares, the days-to-cover ratio is currently 0.5 days. Currently, 10.1% of the shares of the stock are sold short.

Aldeyra Therapeutics Trading Down 1.6%

NASDAQ:ALDX opened at $1.80 on Friday. Aldeyra Therapeutics has a twelve month low of $1.07 and a twelve month high of $6.18. The company's 50 day moving average is $3.55 and its two-hundred day moving average is $4.53. The company has a market cap of $108.32 million, a PE ratio of -3.16 and a beta of 1.34.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last announced its quarterly earnings data on Friday, February 27th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. As a group, analysts expect that Aldeyra Therapeutics will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on ALDX. Wall Street Zen lowered shares of Aldeyra Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, March 21st. HC Wainwright reissued a "neutral" rating and issued a $2.00 target price (down from $10.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, March 18th. Finally, BTIG Research restated a "buy" rating on shares of Aldeyra Therapeutics in a report on Tuesday, March 17th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $5.50.

Aldeyra Therapeutics News Summary

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Neutral Sentiment: Comparative industry analysis published; a head‑to‑head review compares Grifols (GRFS) and Aldeyra but does not announce company‑specific catalysts. Head‑To‑Head Review: Grifols NASDAQ: GRFS versus Aldeyra Therapeutics NASDAQ: ALDX
• Negative Sentiment: Rosen Law Firm reminds Aldeyra purchasers of the May 29, 2026 lead‑plaintiff deadline in a securities class action first filed by the firm — heightens focus on potential claims and recovery efforts. ROSEN Law Firm Notice
• Negative Sentiment: Pomerantz LLP issues an investor alert about a class action and encourages affected investors to contact the firm — another plaintiff‑side step that increases likelihood of coordinated litigation. Pomerantz Investor Alert
• Negative Sentiment: SueWallSt posts an investor alert claiming executives allegedly disregarded FDA requirements and flags the May 29 deadline for lead‑plaintiff motions — allegations that, if sustained, could amplify regulatory and disclosure scrutiny. SueWallSt Alert
• Negative Sentiment: Robbins LLP, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Levi & Korsinsky each issued notices encouraging investors to contact them about the same class period and May 29 deadline — the volume of law‑firm outreach signals broad plaintiff interest and raises the chance of consolidated litigation and settlement pressure. Robbins LLP Notice Bragar Eagel & Squire Bronstein Gewirtz & Grossman Faruqi & Faruqi Levi & Korsinsky

Insider Buying and Selling at Aldeyra Therapeutics

In related news, Director Richard Douglas bought 70,000 shares of the company's stock in a transaction that occurred on Thursday, March 19th. The stock was purchased at an average price of $1.40 per share, for a total transaction of $98,000.00. Following the completion of the transaction, the director owned 195,000 shares in the company, valued at $273,000. The trade was a 56.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 9.60% of the company's stock.

Hedge Funds Weigh In On Aldeyra Therapeutics

Large investors have recently made changes to their positions in the company. AQR Capital Management LLC raised its holdings in shares of Aldeyra Therapeutics by 275.4% during the second quarter. AQR Capital Management LLC now owns 1,473,812 shares of the biotechnology company's stock valued at $5,645,000 after acquiring an additional 1,081,257 shares during the last quarter. 683 Capital Management LLC raised its position in shares of Aldeyra Therapeutics by 86.6% in the fourth quarter. 683 Capital Management LLC now owns 1,530,000 shares of the biotechnology company's stock valued at $7,925,000 after buying an additional 710,000 shares during the last quarter. Kennedy Capital Management LLC raised its position in shares of Aldeyra Therapeutics by 61.9% in the third quarter. Kennedy Capital Management LLC now owns 1,112,213 shares of the biotechnology company's stock valued at $5,806,000 after buying an additional 425,245 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Aldeyra Therapeutics by 590.5% in the third quarter. Bank of America Corp DE now owns 390,078 shares of the biotechnology company's stock valued at $2,036,000 after purchasing an additional 333,587 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Aldeyra Therapeutics by 49.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 947,551 shares of the biotechnology company's stock valued at $4,946,000 after purchasing an additional 313,395 shares during the period. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company's research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company's lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.